Levomilnacipran: Side Effects, Uses & Monitoring
FETZIMA® is indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )].
- Data source
- FDA labeling via NIH DailyMed (label f371258d…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
No structured frequency data available in current labeling. Consult the official label.
Labeled uses (from FDA prescribing information)
FETZIMA® is indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )]. Limitation of Use: FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established.
Conditions associated with Levomilnacipran in labeling
Frequently Asked Questions
What is Levomilnacipran used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Levomilnacipran?
Current labeling for this ingredient does not include a structured frequency table that we can reproduce. Review the official label linked below.
Does Levomilnacipran require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Levomilnacipran.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.